Recent reviews of human studies of exosome material on the skin report that adverse events were uncommon, that the serious reactions followed injection, and that the certainty of the evidence is low or very low [3, 4]. No exosome product is FDA approved [1, 2], so the most useful thing a patient can do is ask what a specific product is, where it came from and how it was handled before it reached the appointment.
This guide sets out seven questions to ask your provider before an exosome add-on, why each one matters, and what a documented answer looks like. Each question points to paperwork a practice can show you, and the last section gathers them into a short checklist you can print or save to your phone.
Regulatory position
The FDA stated in its 2019 public safety notification that there are no FDA-approved exosome products, and its consumer alert says the same [1, 2]. ExaVeyra Sciences supplies exosome material to licensed practitioners, described by its available formats. Whether any product suits a particular patient is a decision for that patient and their licensed provider, and this guide makes no such decision.
Understanding the short answer on topical exosome safety
Gaebe and colleagues reviewed 16 studies of vesicle products on the face in 2026, covering 503 adults, and reported that none of the studies recorded a serious adverse event [3]. The same review rated the certainty of the evidence as low or very low and described the safety signal as short term, citing methodological limitations and short follow-up [3].
Wang, Bajwa and Rivers mapped 17 human studies in a 2026 scoping review and reported that adverse events were uncommon [4]. The serious reactions they listed, including granulomas, tissue necrosis and allergic reactions, followed injection, which sits outside topical use [4].
Those findings describe the studied products under study conditions. A product in a clinic is a different lot from a different maker, which is why the questions below focus on the specific material in front of you.
The source tissue and manufacturer identify what the material is
Exosomes are tiny particles that cells release to carry proteins, lipids and genetic material between cells [11], and products sold under that name come from human, plant and animal sources [6, 13]. Haykal and colleagues named source variability and inconsistent isolation methods among the main open challenges in a 2025 review [11], and Contreras and Ariza-Donado noted in 2026 that many products and studies use the name even though the particles’ endosomal origin is not always demonstrated [12].
A good first question is simple: what cells or tissue does this material come from, and who manufactured it? A practice working from documentation can name the source, the manufacturer and the product line, and can show that the answer matches the label on the vial.
Knauer and colleagues surveyed 20 commercial exosome products in 2026 and reported that they carried minimal information on isolation, processing or shelf life [6]. Rahman and colleagues rated only 18 percent of 18 manufacturers as highly transparent in 2025 [13]. A clear answer on source is one way a product separates itself from that background.
A lot-specific certificate of analysis records what was tested
Every batch of a manufactured material carries a lot number, and a certificate of analysis is the record of the tests run on that lot. A certificate tied to the lot number on the vial tells you the testing applies to the material your provider plans to use, rather than to a sample from years earlier.
The International Society for Extracellular Vesicles publishes a reporting guideline, MISEV2023, that sets out how vesicle material should be described: its source, how it was separated from other particles, and how it was characterized [17]. A characterization panel reports measurements such as particle size and count and the presence of marker proteins, and it can be read against those headings.
| Question for your provider | Why it matters | What a documented answer looks like |
|---|---|---|
| Where does the material come from? | Products differ by source and isolation method (Haykal 2025) | Named source, manufacturer and product line |
| Is there a certificate of analysis for this lot? | Testing applies to a specific batch | A certificate carrying the same lot number as the vial |
| How was the material characterized? | MISEV2023 sets the reporting headings | A characterization panel with particle and marker data |
| How was it stored and shipped? | Vesicle recovery depends on temperature and buffer (Görgens 2022) | Cold-chain records from manufacturer to clinic |
| What does the labeling state? | Intended use shapes regulatory status (FDA) | Labeling that states how and where the material was manufactured |
| Is it FDA approved? | No exosome product is (FDA 2019) | A plain statement that it is not |
| What should I share about my skin and routine? | Topical products can react with opened skin (Soltani-Arabshahi 2014) | A written intake of products, allergies and past reactions |
Storage and shipping conditions shape what reaches the skin
Vesicles are fragile outside the body. Görgens and colleagues tested storage conditions for up to two years in 2022 and reported that recovery depended on buffer and temperature, with losses in plain phosphate-buffered saline and better preservation at minus 80 degrees Celsius in a buffer with human albumin and trehalose [18].
That is why the storage question deserves a specific answer. A practice can tell you how the material was shipped, how it is stored on site, when it was thawed or reconstituted, and whether the temperature record from manufacturer to clinic is complete. ExaVeyra exosome material ships frozen from the manufacturing facility, and the cold-chain records for each lot are available on request.
Product labeling and intended use shape regulatory status
The FDA explains that a product’s regulatory category follows its intended use, which is established in part by the claims made for it, including claims on its labeling [19]. Asking what the labeling states, including how and where the material was made, gives you a document to set beside what your provider tells you about the appointment.
The published reports of serious harm involve injection. AlBargawi described tissue necrosis on both cheeks of one man three days after injections of freeze-dried exosomes in 2025 [14], and Park KY described persistent nodules, inflammation and scarring in four women after products sold for topical use were injected in a nonclinical setting the same year [15].
ExaVeyra supplies exosome material to licensed practitioners, described by its available formats, and its labeling describes the manufacturing conditions, the FDA registration of the manufacturing site and cGMP manufacture. Questions about how that fits a particular appointment belong with your provider.
Understanding the FDA position: no exosome product is approved
The FDA stated in its December 2019 public safety notification that there are currently no FDA-approved exosome products [1]. The notice also reported serious adverse events in patients in Nebraska who received unapproved products marketed as containing exosomes, and it encouraged patients to ask questions and request the facts before any exosome product [1].
The agency’s consumer alert on regenerative medicine products, issued in 2020 and still current, says the FDA has authority over exosome products and that a lot of misleading information online concerns the conditions they can address [2]. Both notices point patients and health care professionals to MedWatch, the FDA program for reporting a side effect or product problem [1, 2, 20].
A trustworthy answer to the approval question is short: no exosome product is FDA approved. A provider or seller who suggests otherwise is giving you a reason to ask more questions.
Published research on side effects of topical use is small and early
The controlled studies are few, and their safety findings are consistent so far. Kwon and colleagues ran a double-blind split-face trial of 25 adults in 2020 with exosome gel applied after fractional CO2 laser sessions, and reported milder redness and shorter downtime on the exosome side [8]. Park GH and colleagues compared an exosome solution with saline after microneedling in 28 participants in 2023 and observed no serious adverse events [9].
Chandran and colleagues ran a phase 1 study in 2025 in which 10 healthy adult volunteers applied an exosome ointment to the forearm three times a day for 20 days. They reported no product-related adverse events, no laboratory abnormalities, and no dryness, itch, redness or swelling where it was applied; four of the authors work for the company that developed the ointment [7].
Reviewers also name risks that the small studies could not rule out. Mahmoud and colleagues listed the potential for infection, an unwanted inflammatory response and the promotion of abnormal cell growth as open safety questions in a 2025 review for dermatologists, and called for better tools to describe what exosome products contain [10].
Your skincare routine belongs in the conversation
Many exosome add-ons follow a procedure that opens small channels in the skin, such as microneedling or a fractional laser. Soltani-Arabshahi and colleagues described three women in 2014 who developed facial granulomas after microneedling with a topical serum, and concluded that a topical product applied with microneedling can carry particles into the deeper skin and trigger a reaction [16].
No exosome product was involved in that report, and it still shows why your provider wants a full picture of what touches your skin. Useful details to share include:
- Every product in your current routine, including retinoids, exfoliating acids, vitamin C serums and prescription creams
- Any known allergies, including to ingredients, preservatives, latex or local numbing creams
- Past reactions to a skincare product, peel, laser or microneedling session
- Recent procedures, sun exposure or tanning in the weeks before your appointment
- Medicines and supplements you take, and any change in your health since your last visit
Your provider decides what those details mean for your appointment. Sharing them in writing gives the practice a record and gives you a copy of what you said.
Understanding what the evidence does not yet show
The topical exosome literature is promising and young, and its limits are specific enough to list. Each one is a reason the documentation questions above carry so much weight.
- Long-term safety: Gaebe 2026 described the safety signal as short term, and Haykal 2025 called for trials of long-term safety [3, 11].
- Small samples: the controlled studies cited here enrolled 25 and 28 participants, and the phase 1 study enrolled 10 [7, 8, 9].
- Low certainty: Gaebe 2026 rated the certainty of evidence low or very low, with risk of bias moderate to critical [3].
- Product differences: Stack 2026 reported heterogeneous, nonstandardized protocols, so a result for one product may not transfer to another [5].
- Thin product information: Knauer 2026 found minimal information on isolation, processing or shelf life among commercial products [6].
- Industry ties: the gels in Kwon 2020 came from their manufacturer, and four Chandran 2025 authors work for the developer [7, 8].
- Skin types: Kwon 2020 enrolled 25 Korean adults with Fitzpatrick skin types III and IV, so results across the full range of skin tones remain to be reported [8].
A printable checklist for the consultation
Bring these questions to your consultation, or save them to your phone. A practice with good documentation can answer each one with a record rather than a reassurance.
- What tissue or cells does this exosome material come from, and who made it?
- May I see the lot number on the vial and the certificate of analysis for that lot?
- Is there a characterization panel, and what does it report?
- How was the material shipped and stored, and is the temperature record complete?
- What does the product labeling state about how the material was made?
- Can you confirm that no exosome product is FDA approved?
- What should I tell you about my skincare, allergies and past reactions?
- How do I reach the practice, and how would a side effect be reported to the FDA through MedWatch?
Documentation is how a practice answers these questions
Every question in this guide has a paper answer, and ExaVeyra Sciences builds its exosome supply around those answers. Every vial carries its lot number, a certificate of analysis is generated for every lot, and the certificate, characterization panel and cold-chain records are available on request; each ExaVeyra certificate reports serological testing for pathogens, and miRNA characterization data is available on request. A practice that carries the material can show a patient the same documents this guide asks about.
As the research grows, patients who ask clear questions and practices that keep clear records move the field forward together. Readers looking for a provider can start with the practitioner directory, and anyone, patient or practice, can ask the scientific team a question. Practices can apply for a verified account without an NPI, and NPI verification unlocks the practitioner portal, exclusive resources and pricing. Product and brand names in the cited studies are trademarks of their respective owners.
Educational Disclaimer: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.
References
- 1.U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019 (content current as of 12/06/2019; verified 9 November 2026). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsAgency safety notification (CBER). Carries in this article: the agency statement that there are currently no FDA-approved exosome products, its report of serious adverse events in patients in Nebraska who received unapproved products marketed as containing exosomes, its questions for patients to ask before any exosome product, and the MedWatch reporting route.
- 2.U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. Issued July 22, 2020; content current as of 04/09/2024; verified 9 November 2026. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomesAgency consumer alert (CBER). Carries in this article: the FDA states it has authority over exosome products, that there is misleading information online about the conditions they can address, that there are no FDA-approved exosome products, and that patients and practitioners can report a bad side effect through MedWatch or contact the agency with questions.
- 3.Gaebe K, Lowe K, Bosnalie D, Khoury S, Villemure Poliquin N, Nichols A. Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review. Facial Plast Surg Aesthet Med. 2026. Published online ahead of print. PMID 42487416. doi:10.1177/26893614261457879PRISMA systematic review with risk-of-bias and GRADE assessment, searches January 2000 to June 2025; 16 studies, 503 participants. Carries in this article: no serious adverse events were reported across the included studies, risk of bias was moderate to critical, GRADE certainty was low or very low, and the authors described the safety signal as short term. Disclosure: academic authors (Canada); no COI statement in the PubMed record.
- 4.Wang OJE, Bajwa BB, Rivers JK. Exosome-Based Therapies in Dermatology: A Scoping Review. J Drugs Dermatol. 2026;25(4):368-376. PMID 41931695. doi:10.36849/jdd.9610Scoping review (PRISMA-ScR) including US and EU trial registries and grey literature; 17 human studies from 2020 to 2025. Carries in this article: adverse events were uncommon, and the granulomas, necrosis and allergic reactions it lists followed injection; limitations of small samples, short follow-up, single-arm designs and potential conflicts of interest. Disclosure: no COI statement in the PubMed record.
- 5.Stack ER, Spongberg C, Braud SC, Stanton WN, Elway M. Clinical Advances in Exosome-Based Therapies for Aesthetic Medicine: A Systematic Review and Meta-analysis of Human Clinical Trials. Aesthet Surg J. 2026;46(12 Suppl 2):S13-S25. PMID 41800726. doi:10.1093/asj/sjaf178Systematic review and random-effects meta-analysis, searches to February 2025; 39 human studies, 26 of them on skin outcomes. Carries in this article: the size of the human literature and the authors’ caution that heterogeneity and nonstandardized protocols limit how far results generalize. Disclosure: published in a journal supplement on exosomes; the PubMed record carries no funding or COI statement.
- 6.Knauer G, Chang A, Gupta A, Brownstone N, Mejia N, Bauman S, et al. Clinical Evidence and Commercial Landscape of Topical Exosomes for Skin Rejuvenation: A Scoping Review. Aesthet Surg J. 2026;46(11):NP148-NP157. PMID 42411735. doi:10.1093/asj/sjag141Scoping review with a librarian-reviewed search (2,394 records screened) plus a survey of the first 20 commercial exosome products in an online shopping search; 18 human studies, 8 of them topical application alone. Carries in this article: human studies of topical exosomes remain scarce, and commercial products carried minimal information on isolation, processing or shelf life. Disclosure: academic authors (USA); no COI statement in the PubMed record.
- 7.Chandran NS, Bhupendrabhai MN, Tan TT, Zhang B, Lim SK, Choo ABH, Lai RC. A phase 1, open-label study to determine safety and tolerability of the topical application of mesenchymal stem/stromal cell (MSC) exosome ointment to treat psoriasis in healthy volunteers. Cytotherapy. 2025;27(5):633-641. PMID 39918488. doi:10.1016/j.jcyt.2025.01.007Phase 1, open-label tolerability study; an MSC exosome ointment applied to the forearm three times a day for 20 days in healthy adult volunteers (Singapore); n = 10. Carries in this article: the study reported no product-related adverse events, no laboratory abnormalities and no dryness, itch, redness or swelling at the application site. Disclosure: four authors are employees of the company that developed the ointment.
- 8.Kwon HH, Yang SH, Lee J, Park BC, Park KY, Jung JY, et al. Combination Treatment with Human Adipose Tissue Stem Cell-derived Exosomes and Fractional CO2 Laser for Acne Scars: A 12-week Prospective, Double-blind, Randomized, Split-face Study. Acta Derm Venereol. 2020;100(18):adv00310. PMID 33073298. PMC9309822. doi:10.2340/00015555-3666Prospective, double-blind, randomized, split-face trial over 12 weeks with three fractional CO2 laser sessions (Korea); n = 25. Carries in this article: the authors reported milder redness and shorter downtime on the side that received the exosome gel after each session. Participants were 25 Korean adults with Fitzpatrick skin types III and IV (full text). Disclosure: the exosome and control gels were supplied by their manufacturer; the authors declared no conflicts of interest.
- 9.Park GH, Kwon HH, Seok J, Yang SH, Lee J, Park BC, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. J Cosmet Dermatol. 2023;22(12):3418-3426. PMID 37377400. doi:10.1111/jocd.15872Prospective, randomized, split-face comparative study over 12 weeks, three microneedling sessions three weeks apart, saline on the control side (Korea); n = 28. Carries in this article: the authors observed no serious adverse events. Disclosure: National Research Foundation of Korea grants listed in the PubMed record; no COI statement in the record.
- 10.Mahmoud RH, Peterson E, Badiavas EV, Kaminer M, Eber AE. Exosomes: A Comprehensive Review for the Practicing Dermatologist. J Clin Aesthet Dermatol. 2025;18(4):33-40. PMID 40256340. PMC12007658Clinical narrative review by academic dermatologists (USA). Carries in this article: clinical studies are lacking, and the authors list the potential risks of infection, unwanted inflammatory response and promotion of malignancy as open safety questions. Disclosure: the authors declared no conflicts of interest relevant to the article.
- 11.Haykal D, Wyles S, Garibyan L, Cartier H, Gold M. Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges. J Drugs Dermatol. 2025;24(1):12-18. PMID 39761139. doi:10.36849/JDD.8872Literature review of 56 references from 2014 to 2024. Carries in this article: the authors state there are no FDA-approved exosomes and name inconsistent isolation methods, source variability and the need for trials of long-term safety as open challenges. Disclosure: no COI statement in the PubMed record.
- 12.Contreras C, Ariza-Donado A. Extracellular Vesicles in Regenerative and Cosmetic Medicine: Safety, Clinical Effectiveness, Therapeutic Applications, and Regulatory Challenges. Int J Mol Sci. 2026;27(12):5541. PMID 42353255. PMC13299476. doi:10.3390/ijms27125541Narrative review of Scopus and PubMed studies with a qualitative survey of 12 aesthetic physicians (Colombia). Carries in this article: many products called exosomes do not demonstrate endosomal origin, the literature varies by source and isolation, and reports of adverse reactions to unapproved products marketed as exosome-based call for stronger oversight. Disclosure: the authors declared no conflict of interest.
- 13.Rahman E, Sayed K, Rao P, Abu-Farsakh H, Sadeghi-Esfahlani S, Garcia PE, et al. Exosome Revolution or Marketing Mirage? AI-Based Multi-domain Evaluation of Claims, Scientific Evidence, Transparency, Public Sentiment, and Media Narratives. Aesthetic Plast Surg. 2025;49(12):3454-3479. PMID 40055226. doi:10.1007/s00266-025-04712-3Cross-sectional, AI-assisted analysis of 18 manufacturers, 70 product formulations, about 2.7 million social media posts and 37,437 consumer reviews. Carries in this article: 18 percent of manufacturers rated high on transparency, growth factor content varied by source, and 27 percent of social media claims were rated misleading. Disclosure: the authors declared no conflicts of interest.
- 14.AlBargawi S. Necrosis Following Dermal Injection of Lyophilized Exosomes: A Case Report. J Cosmet Dermatol. 2025;24(8):e70387. PMID 40820962. PMC12359287. doi:10.1111/jocd.70387Case report; one adult man with tissue necrosis of both cheeks three days after multiple injections of lyophilized exosomes into the skin (Saudi Arabia); n = 1. Carries in this article: a serious adverse event after injection, a route the published topical studies did not test. Disclosure: the author declared no conflicts of interest.
- 15.Park KY. Adverse Reactions Following Intradermal Injection of Exosome-Based Formulations: A Case Series. J Cosmet Dermatol. 2025;24(10):e70520. PMID 41097876. PMC12528963. doi:10.1111/jocd.70520Case series; four adult women after injection into the skin of exosome-containing cosmetic products in a nonclinical setting (South Korea); n = 4. Carries in this article: persistent redness, nodules, granulomatous inflammation and scarring after off-label injection of products sold for topical use. Disclosure: the author declared no conflicts of interest.
- 16.Soltani-Arabshahi R, Wong JW, Duffy KL, Powell DL. Facial allergic granulomatous reaction and systemic hypersensitivity associated with microneedle therapy for skin rejuvenation. JAMA Dermatol. 2014;150(1):68-72. PMID 24258303. doi:10.1001/jamadermatol.2013.6955Case series; three women with facial granulomas after microneedling with a topical serum, two with a positive patch test to the same branded serum (USA); n = 3. Carries in this article: the authors concluded that a topical product applied with microneedling can carry immunogenic particles into the dermis, the reason a patient’s products and past reactions belong in the conversation. No exosome product was involved.
- 17.Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al; MISEV Consortium; Théry C, Witwer KW. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. PMID 38326288. PMC10850029. doi:10.1002/jev2.12404International Society for Extracellular Vesicles reporting guideline, compiled with ISEV task forces and more than 1,000 researchers. Carries in this article: the reference standard for source description, separation from non-vesicular particles and characterization, the headings a certificate of analysis and characterization panel can be read against. Disclosure: many consortium authors list EV company affiliations, declared in full in the article.
- 18.Görgens A, Corso G, Hagey DW, Jawad Wiklander R, Gustafsson MO, Felldin U, et al. Identification of storage conditions stabilizing extracellular vesicles preparations. J Extracell Vesicles. 2022;11(6):e12238. PMID 35716060. PMC9206228. doi:10.1002/jev2.12238In vitro stability study up to two years across buffers and temperatures, vesicles from several cell sources. Carries in this article: the authors reported that vesicle recovery depended on buffer and temperature, with losses in plain PBS and better preservation at minus 80 degrees in a buffer with human albumin and trehalose, including across freeze-thaw cycles. Disclosure: several authors list affiliation with an EV therapeutics company.
- 19.U.S. Food and Drug Administration. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?). Content current as of 09/11/2024; verified 9 November 2026. https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soapAgency guidance page on the FD&C Act definitions. Carries in this article: a product’s regulatory category follows its intended use, established in part by the claims made for it, which is why labeling matters and why a supplier describes a product without naming a condition.
- 20.U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Content current as of 11/03/2026; verified 9 November 2026. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-programAgency program page. Carries in this article: the route by which patients and health care professionals report a side effect or product problem to the FDA, the route both FDA exosome notices point to.